SCHEMBL212306

SCHEMBL212306

CSc1ncc(C#N)c(N)n1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TP53 P04637 2/20 0.58
KMT2A Q03164 4/20 0.57
KDM4E B2RXH2 3/20 0.57
GAA P10253 2/20 0.57
HSD17B10 Q99714 2/20 0.57
TSHR P16473 2/20 0.57
MEN1 O00255 2/20 0.57
HTT P42858 1/20 0.57
L3MBTL1 Q9Y468 1/20 0.57
CSNK1A1 P48729 1/20 0.55
CLK4 Q9HAZ1 1/20 0.55
ALDH1A1 P00352 4/20 0.54
USP2 O75604 1/20 0.49
ALOX15 P16050 1/20 0.49
MAPK1 P28482 1/20 0.49
PKM P14618 1/20 0.47
NPC1 O15118 1/20 0.42
RAB9A P51151 1/20 0.42
CYP3A4 P08684 1/20 0.40
CYP2D6 P10635 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6248337 0.81 TP53 (0.62) TP53KMT2AKDM4EGAAHSD17B10
SCHEMBL810345 0.81 KMT2A (0.69) TP53KMT2AKDM4EGAAHSD17B10
SCHEMBL440008 0.78 KMT2A (0.42) TP53KMT2AKDM4EGAAHSD17B10
SCHEMBL1227312 0.78 KDM4E (0.38) TP53KMT2AKDM4EGAAHSD17B10
SCHEMBL31279583 0.78 KMT2A (0.42) TP53KMT2AKDM4EGAAHSD17B10
SCHEMBL8397028 0.76 KMT2A (0.42) TP53KMT2AKDM4EGAAHSD17B10
SCHEMBL25204937 0.75 KDM4E (0.45) TP53KMT2AKDM4EGAAHSD17B10
SCHEMBL2480844 0.75 KDM4E (0.45) KMT2AKDM4EGAAHSD17B10TSHR
SCHEMBL3970187 0.75 LRRK2 (0.44) TP53KMT2AKDM4EGAAHSD17B10
SCHEMBL584580 0.75 CSNK1A1 (0.60) TP53KMT2AKDM4EGAAHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3727435-B1 BIVALENT NUCLEIC ACID LIGANDS AND USES THEREFOR UNIV CARNEGIE MELLON (US) 2026-02-18 EP disclosed
US-20250152593-A1 p38 MAPK INHIBITORS AND USES THEREOF HOPE CITY (US) 2025-05-15 US disclosed
CN-111757935-B Bivalent nucleic acid ligands and uses thereof 卡耐基梅隆大学 2025-02-21 CN disclosed
WO-2023147418-A1 PARP7 INHIBITORS GILEAD SCIENCES, INC. (US) 2023-08-03 WO disclosed
EP-3727435-A1 BIVALENT NUCLEIC ACID LIGANDS AND USES THEREFOR CARNEGIE MELLON UNIVERSITY (US) 2020-10-28 EP disclosed
CN-111757935-A Bivalent nucleic acid ligand and use thereof 卡耐基梅隆大学 2020-10-09 CN disclosed
US-20200318195-A1 Bivalent Nucleic Acid Ligands and Uses Therefor CARNEGIE MELLON UNIVERSITY 2020-10-08 US disclosed
US-20200318195-A1 Bivalent Nucleic Acid Ligands and Uses Therefor CARNEGIE MELLON UNIVERSITY 2020-10-08 US disclosed
US-10370415-B2 Divalent nucleobase compounds and uses therefor CARNEGIE MELLON UNIVERSITY (US) 2019-08-06 US disclosed
EP-2376493-B1 DIHYDROPYRIMIDOPYRIMIDINE DERIVATIVE MSD KK (JP) 2016-10-05 EP disclosed
EP-1651648-A2 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS IRM LLC (BM) 2006-05-03 EP disclosed
US-20050245518-A1 Antiproliferative agents METHYLGENE, INC. 2005-11-03 US disclosed
WO-2005092899-A1 INHIBITORS OF HISTONE DEACETYLASE METHYLGENE INC. (CA) 2005-10-06 WO disclosed
US-20050222177-A1 Compounds and compositions as protein kinase inhibitors IRM LLC (BM) 2005-10-06 US disclosed
US-20050187230-A1 Compounds and compositions as protein kinase inhibitors IRM LLC (BM) 2005-08-25 US disclosed
WO-2005044008-A2 2 -AMINOTHIOPHENE COMPOUNDS AS FUNGICIDES SYNGENTA PARTICIPATIONS AG (CH) 2005-05-19 WO disclosed
WO-2005034869-A2 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS IRM LLC (BM) 2005-04-21 WO disclosed
WO-2005011597-A2 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS IRM LLC (BM) 2005-02-10 WO disclosed
US-20040044012-A1 Bicyclic pyrimidines and bicyclic 3,4-dihydropyrimidines as inhibitors of cellular proliferation DOBRUSIN ELLEN MYRA (US) 2004-03-04 US disclosed
US-4323681-A IMMUNOMODULATOR AGENTS HAVING STIMULANT OR SUPPRESSANT EFFECT FOR TREATMENT OF AUTOIMMUNE DISORDERS AMERICAN HOME PRODUCTS CORPORATION (US) 1982-04-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040044012-A1 Bicyclic pyrimidines and bicyclic 3,4-dihydropyrimidines as inhibitors of cellular proliferation CCNI, CCNH, CCNA1 TP53 375/4885KMT2A 2878/4885KDM4E 3108/4885
US-20050187230-A1 Compounds and compositions as protein kinase inhibitors FYN, LCK, SRC TP53 890/4885KMT2A 1842/4885KDM4E 1492/4885
US-20250152593-A1 p38 MAPK INHIBITORS AND USES THEREOF MAPK8, MAPK1, MAPK7 TP53 982/4885KMT2A 2691/4885KDM4E 4299/4885
US-10370415-B2 Divalent nucleobase compounds and uses therefor DNTT, POLM, POLL TP53 553/4885KMT2A 2921/4885KDM4E 4851/4885
US-20050245518-A1 Antiproliferative agents HDAC1, HDAC11, HDAC5 TP53 115/4885KMT2A 123/4885KDM4E 337/4885
US-20050222177-A1 Compounds and compositions as protein kinase inhibitors BMX, FES, FRK TP53 1115/4885KMT2A 2082/4885KDM4E 2488/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.